Pharmacodynamics of telavancin studied in an in vitro pharmacokinetic model of infection

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 2, 2011, Pages 867-873

  MacGowan, Alasdair P ^a   Noel, Alan R ^a   Tomaselli, Sharon ^a   Elliott, Heather C ^a   Bowker, Karen E ^a  

^a SOUTHMEAD HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

TEICOPLANIN; TELAVANCIN; VANCOMYCIN;

ARTICLE; BACTERIAL GROWTH; BACTERIAL INFECTION; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; BODY WEIGHT; CONTROLLED STUDY; DRUG EFFICACY; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; IN VITRO STUDY; IN VIVO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; VANCOMYCIN RESISTANT ENTEROCOCCUS;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; CULTURE MEDIA; ENTEROCOCCUS; GRAM-POSITIVE BACTERIAL INFECTIONS; GRAM-POSITIVE COCCI; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; STAPHYLOCOCCUS AUREUS; TEICOPLANIN; VANCOMYCIN;

EID: 78751681331     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00933-10     Document Type: Article

References (27)

1. Andrews, J. M. 1999. Microbiological assays, p. 45-63. In D. S. Reeves, R. Wise, J. M. Andrews, and L. O. White (ed.), Clinical microbiological assays. Oxford University Press, Oxford, United Kingdom.
2. Bowker, K. E., A. R. Noel, and A. P. MacGowan. 2009. Comparative antibacterial effects of daptomycin, vancomycin and teicoplanin studied in an in vitro pharmacokinetic model of infection. J. Antimicrob. Chemother. 64: 1044-1051.
3. Clinical and Laboratory Standards Institute. 2005. Performance standards for antimicrobial susceptibility testing. CLSI document M100-S16. Clinical and Laboratory Standards Institute, Wayne, PA.
4. Craig, W. A., and D. R. Andes. 2006. In vivo pharmacodynamics of vancomycin against VISA, heteroresistant VISA and VSSA in the neutropenic murine thigh infection model, abstr. A-644, p. 16. Abstr. 46th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
5. Dudley, M., D. Griffith, E. Corcoran, C. Liu, K. Sorensen, V. Tembe, D. Cotter, S. Chamberland, and S. Chen. 1999. Pharmacokinetic-pharmacodynamic indices for vancomycin treatment of susceptible and intermediate S. aureus in the neutropenic mouse thigh model, abstr. 2031, p. 49. Abstr. 39th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
6. European Committee on Antimicrobial Susceptibility Testing. 2010. Rationale for the EUCAST clinical breakpoints version 2.1, 17 June 2010. Teicoplanin. http://www.eucast.org/filesadmin/src/media/PDFs/EUCAST-files/ Rationale-documents.
7. European Committee on Antimicrobial Susceptibility Testing. 2010. Rationale for the EUCAST clinical breakpoints version 2.1, 17 June 2010. Vancomycin. http://www.eucast.org/filesadmin/src/media/PDFs/EUCAST-files/ Rationale-documents.
8. Hegde, S. S., N. Reyes, T. Wiens, N. Vanasse, R. Skinner, J. McCullough, K. Kaniga, J. Pace, R. Thomas, J.-P. Shaw, G. Obedenico, and J. K. Judice. 2004. Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent against Gram-positive bacteria. Antimicrob. Agents Chemother. 48:3043-3050.
9. Jansen, W. T. M., A. Verel, J. Verhoef, and D. Milatovic. 2007. In vitro activity of telavancin against Gram-positive clinical isolates recently obtained in Europe 2007. Antimicrob. Agents Chemother. 51:3420-3424.
10. King, A., I. Phillips, and K. Kaniga. 2004. Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration-dependent antiinfective with multiple mechanisms of action against Gram-positive bacteria. J. Antimicrob. Chemother. 53:797-803.
11. Leonard, S. N., V. Vidaillac, and M. J. Rybak. 2009. Activity of telavancin against staphylococcus aureus strains with various vancomycin susceptibilities in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations. Antimicrob. Agents Chemother. 53:2928-2933.
12. Leuthner, K. D., C. M. Cheung, and M. J. Rybak. 2006. Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus. J. Antimicrob. Chemother. 58:338-342.
13. Lodise, T. P., M. Gotfried, S. Barriere, and G. L. Drusano. 2008. Telavancin penetration into human epithelial lining fluid determined by population pharmacokinetic modelling and Monte Carlo simulation. Antimicrob. Agents Chemother. 52:2300-2304.
14. MacGowan, A. P., D. S. Reeves, and R. Wise. 1999. Clinical interpretation of antimicrobial assays, p. 1-11. In D. S. Reeves, R. Wise, J. M. Andrews, and L. O. White (ed.), Clinical antibiotic assays. Oxford University Press, Oxford, United Kingdom.
15. MacGowan, A. P., C. A. Rogers, H. A. Holt, and K. E. Bowker. 2003. Activities of moxifloxacin against, and emergence of resistance in Streptococcus pneumoniae and Pseudomonas aeruginosa in an in vitro pharmacokinetic model. Antimicrob. Agents Chemother. 47:1088-1095.
16. MacGowan, A. P., K. E. Bowker, and A. R. Noel. 2008. Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO 4908463/CS-023, in an invitro pharmacokinetic model of Staphylococcus aureus infection. Antimicrob. Agents Chemother. 52:1401-1406.
17. Madrigal, A. G., L. Basuino, and H. F. Chambers. 2005. Efficacy of telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycin intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 49:3163-3165.
18. Miró, J. M., C. G. Maria, X. Armero, E. de-Lazzari, D. Soy, A. Moreno, A. del Rio, M. Almela, C. A. Mestres, J. M. Gatell, M.-T. J-de Anta, F. Marco, and the Hospital Clinical Experimental Endocarditis Group. 2007. Efficacy of telavancin in the treatment of experimental endocarditis due to glycopeptide-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 51:2373-2377.
19. Odenholt, I., E. Lowdin, and O. Cars. 2007. Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum in an in vitro kinetic model. Antimicrob. Agents Chemother. 51:3311-3316.
20. Pace, J. L., K. Krause, D. Johnston, D. Debabov, T. Wu, L. Farrington, C. Lane, D. L. Higgins, B. Christensen, J. K. Judice, and K. Kaniga. 2003. In vitro activity of TD-6424 against Staphylococcus aureus. Antimicrob. Agents Chemother. 47:3602-3604.
21. Pankuch, G. A., and P. C. Appelbaum. 2009. Postantibiotic effects of telavancin against 16 Gram-positive organisms. J. Antimicrob. Chemother. 53: 1275-1277.
22. Reyes, N., R. Skinner, K. Kaniga, K. M. Krause, J. Shelton, G. P., Obedencio, A. Gough, M. Conner, and S. S. Hedge. 2005. Efficacy of telavancin (TD-6424), a rapidly bactericidal lipoglycopeptide with multiple mechanisms of action, in a murine model of pneumonia induced by methicillin resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 49:4344-4346.
23. Reyes, N., R. Skinner, B. M. Benton, K. M. Krause, J. Shelton, G. Obedencio, and S. S. Hedge. 2006. Efficacy of telavancin in a murine model of bacteraemia induced by methicillin resistant Staphylococcus aureus. J. Antimicrob. Chemother. 58:462-465.
24. Shaw, J. P., J. Seroogy, K. Kaniga, D. L. Higgins, M. Kitt, and S. Barriere. 2005. Pharmacokinetics, serum inhibitory and bactericidal activity and safety of telavancin in healthy subjects. Antimicrob. Agents Chemother. 49:195-201.
25. Stryjewski, M. E., V. H. Chu, W. D. O'Riordan, B. L. Warren, L. M. Dunbar, D. M. Young, M. Vallee, V. G. Fowler, J. Morganroth, S. L. Barriere, M. M. Kitt, and G. R. Covey. 2006. Telavancin versus standard therapy for the treatment of complicated skin and skin structure infections caused by Grampositive bacteria: FAST 2 Study. Antimicrob. Agents Chemother. 50:862-867.
26. Turner, J., R. A. Howe, M. Wootton, K. E. Bowker, H. A. Holt, V. Salisbury, P. M. Bennett, T. R. Walsh, and A. P. MacGowan. 2001. The activity of vancomycin against heterogeneous vancomycin-intermediate methicillin-resistant Staphylococcus aureus explored using an in vitro pharmacokinetic model. J. Antimicrob. Chemother. 48:727-730.
27. Wootton, M., R. A. Howe, R. Hillman, T. R. Walsh, P. M. Bennett, and A. P. MacGowan. 2001. A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital. J. Antimicrob. Chemother. 47:399-403.